Stories about Pediatrics

Subscribe to Pediatrics

04.12.2020 – 12:14

Technische Universität München
WHO guidelines on physical activity call for more exercise

TECHNICAL UNIVERSITY OF MUNICH Corporate Communications Center phone: +49 89 289 10510 - e-mail: presse@tum.de - web: www.tum.de This text on the web: https://www.sg.tum.de/en/news-en/news-singleview-fakultaet-en/article/prof-oberhoffer-fritz-fordert-nach-aktuellen-who-empfehlungen-kinder-und-jugendliche-muessen-sich-en/ High resolution images: https://mediatum.ub.tum.de/1581167 NEWS RELEASE WHO guidelines on physical ...

more
01.12.2020 – 09:00

Norgine
Norgine B.V. Announces New European Healthcare Subsidiary To Strengthen Its Consumer Healthcare Portfolio

Amsterdam, The Netherlands (ots/PRNewswire) - Norgine B.V. ("Norgine"), today announced the establishment of a wholly-owned subsidiary, Norgine Healthcare B.V. ("Norgine Healthcare"), which will be dedicated to consumer healthcare. To view the Multimedia News Release, please click: ...

more
15.10.2020 – 15:03

Volvo Car Corporation
Volvo's Backwards Thinking: why facing rearwards is the safest way of travel for your child

Gothenburg, Sweden (ots/PRNewswire) - Volvo Cars, a global leader in car safety, recommends to seat small children up to the age of four facing rearwards inside cars, as decades of safety research demonstrate this to be the safest option of travel for small children. Backed by those decades of research, Volvo Cars safety experts see rearward-facing travel for small ...

more
30.09.2020 – 13:00

BrainRepair UG

Regulatory breakthrough for BrainRepair UG start-up - Stem cell treatment for newborns /EMA Orphan Drug Designation is followed by agreement on Paediatric Investigation Plan

more
14.09.2020 – 00:05

Merck KGaA
Merck Advances Oncology Portfolio and Pipeline with New and Long-term Data in Multiple Cancers at ESMO 2020

Darmstadt, Germany (ots/PRNewswire) - · New analyses from Phase III JAVELIN Bladder 100 study of BAVENCIO®* assess efficacy across subgroups, patient-reported outcomes and exploratory biomarkers in advanced urothelial cancer · Overall efficacy data, and analyses of brain metastases and HRQoL for tepotinib? from ...

more
09.09.2020 – 07:00

UCB Pharma
Final Phase II Results for UCB's Rozanolixizumab in Primary Immune Thrombocytopenia (ITP) Published in Blood Advances

Brussels (ots/PRNewswire) - - Phase II data demonstrated clinically meaningful platelet count increases with meaningful decreases in IgG concentration - Rozanolixizumab's subcutaneous route of administration shows potential to deliver targeted individualized patient care for people living with Primary Immune ...

more
01.07.2020 – 08:24

CARAG AG
Carag Receives U.S. FDA IDE Approval to Conduct Clinical Study of First Transcatheter Septal Occluder With Bioresorbable, Metal-free Framework

Baar, Switzerland (ots/PRNewswire) - The U.S. trial for CE-marked CBSO is designed to enroll up to 250 patients in a staged study approach CARAG AG, a privately-held Swiss medical device development company, today announced receiving U.S. Food and Drug Administration (FDA) Investigational Device Exemption (IDE) ...

more
04.06.2020 – 13:20

Else Kröner-Fresenius-Stiftung

Groundbreaking Gene Therapies for Hereditary Diseases / Alessandro Aiuti, a physician and research scientist from Milan, receives the Else Kröner Fresenius Prize for Medical Research 2020 endowed with 2.5 million euros

more
13.05.2020 – 13:03

Technische Universität München
A disease trigger for pancreatitis has been identified

TECHNICAL UNIVERSITY OF MUNICH Corporate Communications Center phone: +49 8161/ 71-5403 - e-mail: presse@tum.de - web: www.tum.de This text on the web: https://www.tum.de/nc/en/about-tum/news/press-releases/details/36036/ High resolution images: https://mediatum.ub.tum.de/1545776 NEWS RELEASE A Calcium channel is involved in the development of pancreatitis A disease trigger for pancreatitis has been identified One factor ...

more
31.03.2020 – 18:00

Novo Nordisk A/S
Saxenda® Demonstrated Improvements in BMI and Body Weight in Adolescents With Obesity

Bagsværd, Denmark (ots/PRNewswire) - Novo Nordisk today announced that the New England Journal of Medicine published results of a phase 3 trial evaluating the investigational use of Saxenda® (liraglutide 3.0 mg) in adolescents (aged ...

more
10.03.2020 – 08:00

CARAG AG
Carag First-ever Septal Occluder With Bioresorbable, Metal-free Framework Available to Patients Through New European Registry

Baar, Switzerland and Berlin (ots/PRNewswire) - First 3-year-old patient successfully implanted and discharged from hospital in Berlin CARAG AG, a Swiss privately held medical device development company, announced today the successful implantation of the first-ever transcatheter septal occluder with bioresorbable, ...

more
24.02.2020 – 13:02

Syntellix AG
Positive signs for further growth in Asia: Syntellix receives product approvals in Malaysia and Myanmar earlier than planned

Hannover (ots) - - MAGNEZIX® StarFuse® and Compression Screw 4.8 (CSc 4.8) product lines receive approval from Malaysian authorities eight months ahead of schedule. - Two product families, MAGNEZIX® Compression Screw (CS) and MAGNEZIX® Cortical Bone Screw (CBS), also granted approval in Myanmar, six months ...

more
17.02.2020 – 10:00

Fresenius Kabi Deutschland GmbH
A new expert consensus publication provides practical guidance on the use of omega-3 fatty acids in parenteral nutrition

Bad Homburg (ots) - Fresenius Kabi, a global leader in clinical nutrition, announces that the Journal of Parenteral and Enteral Nutrition (JPEN) has recently published "Lipids in Parenteral Nutrition: Translating Guidelines into Clinical Practice".(1) The publication represents the largest set of expert consensus ...

more
07.02.2020 – 10:34

Stada Arzneimittel

2
STADA to acquire established OTC and food supplement portfolio in the Philippines
One document
more
28.10.2019 – 19:00

Merck KGaA
European Commission Approves BAVENCIO® (avelumab) Plus Axitinib Combination for First-Line Treatment of Patients With Advanced Renal Cell Carcinoma

Darmstadt, Germany, and New York (ots/PRNewswire) - Not intended for US, Canada and UK-based media -- EU approval based on JAVELIN Renal 101 trial results demonstrating significant improvement in progression-free survival with BAVENCIO in combination with axitinib compared with sunitinib -- Combination regimen ...

more
23.10.2019 – 16:23

UEG Week
UEG Week Exhibition Celebrates 50 Years of Colonoscopy in Preventing and Diagnosing Gastrointestinal Diseases, Including Colorectal Cancer

Barcelona, Spain (ots/PRNewswire) - An interactive exhibition celebrating the 50th anniversary since the completion of the first successful colonoscopy has been launched at the United European Gastroenterology (UEG) Week in Barcelona. The educational exhibition is jointly supported by Norgine, Fujifilm and Olympus ...

more
26.06.2019 – 16:30

Campus Klinik an der Ruhr-Universität Bochum

Unique index at birth predicts disability at 4 years of age / Fetal Growth determines preschool performance

more
26.03.2019 – 15:29

Mallinckrodt Plc.
Mallinckrodt Announces 2019 Investigator Award for Pioneering Efforts in ECP Immunomodulation

Staines-Upon-Thames, England (ots/PRNewswire) - EUR50,000 award goes to Newcastle University, in collaboration with Medical University, Graz and Newcastle Hospitals NHS Foundation Trust Mallinckrodt plc (NYSE: MNK), a leading specialty pharmaceutical company, today announced the recipient of 2019's Advancing Extracorporeal Photopheresis (ECP) Immunomodulation ...

more
20.03.2019 – 09:01

Primex Pharmaceuticals
Primex Pharmaceuticals and Nordic Group Sign a Strategic Partnership to Commercialise OZALIN® in France

Paris and Zug, Switzerland (ots/PRNewswire) - Nordic Group, a pharmaceutical company focusing on the development and commercialisation of hospital and orphan products, and Primex Pharmaceuticals AG, an innovative global Anaesthesia pharmaceutical company, announced a strategic agreement today to launch OZALIN® in ...

more
21.02.2019 – 08:01

Primex Pharmaceuticals
Primex Pharmaceuticals and POA Pharma Sign a Strategic Partnership to Commercialise OZALIN in the Nordic Region

Gothenburg, Sweden and Zug, Switzerland (ots/PRNewswire) - POA Pharma Scandinavia AB, a market-oriented Boutique Healthcare Company, working in close contact with healthcare organizations, professionals and hospitals in Nordic countries and Primex Pharmaceuticals AG, an innovative Anaesthesia pharmaceutical company, ...

more
16.02.2019 – 23:10

Merck KGaA
Pivotal Phase III Data for BAVENCIO® (avelumab) Plus INLYTA® (axitinib) in Advanced Renal Cell Carcinoma Published in the New England Journal of Medicine

Darmstadt, Germany and New York (ots/PRNewswire) - Not intended for US, Canada and UK-based media - JAVELIN Renal 101 shows significant improvement in progression-free survival with a hazard ratio of 0.69 in patients regardless of PD-L1 expression - US FDA has granted Priority Review to BAVENCIO plus INLYTA for ...

more
11.02.2019 – 23:55

Merck KGaA
FDA Accepts sBLA and Grants Priority Review for BAVENCIO® (avelumab) Plus INLYTA® (axitinib) for the Treatment of Advanced Renal Cell Carcinoma

Darmstadt, Germany and New York (ots/PRNewswire) - Not intended for US, Canada and UK-based media Merck and Pfizer Inc. (NYSE: PFE) today announced that the US Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for BAVENCIO® (avelumab) in ...

more
05.02.2019 – 14:15

CartiHeal (2009) Ltd.
CartiHeal Performs First Agili-C(TM) Cartilage Repair Implantation Procedures at Missouri Orthopaedic Institute

Kfar Saba, Israel (ots/PRNewswire) - Four patients enrolled and operated on by sports medicine surgeon Dr. Seth L. Sherman, MD Seth L. Sherman, MD, a sports medicine orthopaedic surgeon at Missouri Orthopaedic Institute, recently became one of the first American surgeons to enroll patients in a clinical research ...

more
28.09.2018 – 08:41

Novo Nordisk A/S
New Phase 2 Data for Somapacitan Demonstrate Its Potential as an Efficacious Once-weekly Treatment for Childhood Growth Hormone Deficiency

Athens, Greece (ots/PRNewswire) - Somapacitan, a novel growth hormone derivative in development for once-weekly administration of growth hormone, matched the therapeutic benefits of once-daily Norditropin® (somatropin) in a phase 2 trial in children with growth hormone deficiency.[1] There are currently no approved ...

more
11.09.2018 – 14:31

Merck KGaA
BAVENCIO® (avelumab) Plus INLYTA® (axitinib) Significantly Improved Progression-Free Survival in Previously Untreated Patients With Advanced Renal Cell Carcinoma in Phase III Study

Darmstadt, Germany and New York (ots/PRNewswire) - Not intended for US, Canada and UK-based media - First positive Phase III immunotherapy trial in combination with a tyrosine kinase inhibitor (TKI) in any tumor type - Results significant in both PDL1+ and all-comer populations - Alliance plans to pursue a ...

more

1